Validation of a Multiomic Model of Plasma Extracellular Vesicle Pd-L1 and Radiomics for Prediction of Response to Immunotherapy in NSCLC

Authors

Diego de Miguel-Perez
Murat Ak
Priyadarshini Mamindla
Alessandro Russo
Serafettin Zenkin
Nursima Ak
Vishal Peddagangireddy
Luis Lara-Mejia
Muthukumar Gunasekaran
Andres F Cardona
Aung Naing
Fred R Hirsch
Oscar Arrieta
Rivka R Colen
Christian Rolfo

Publication Date

3-15-2024

Journal

Journal of Experimental & Clinical Cancer Research

Abstract

BACKGROUND: Immune-checkpoint inhibitors (ICIs) have showed unprecedent efficacy in the treatment of patients with advanced non-small cell lung cancer (NSCLC). However, not all patients manifest clinical benefit due to the lack of reliable predictive biomarkers. We showed preliminary data on the predictive role of the combination of radiomics and plasma extracellular vesicle (EV) PD-L1 to predict durable response to ICIs.

MAIN BODY: Here, we validated this model in a prospective cohort of patients receiving ICIs plus chemotherapy and compared it with patients undergoing chemotherapy alone. This multiparametric model showed high sensitivity and specificity at identifying non-responders to ICIs and outperformed tissue PD-L1, being directly correlated with tumor change.

SHORT CONCLUSION: These findings indicate that the combination of radiomics and EV PD-L1 dynamics is a minimally invasive and promising biomarker for the stratification of patients to receive ICIs.

Keywords

Humans, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, B7-H1 Antigen, Radiomics, Multiomics, Prospective Studies, Biomarkers, Tumor, Immunotherapy, Extracellular Vesicles

Comments

Supplementary Materials

Data Availability Statement

PMID: 38486328